These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 10964546)
1. Characterization of human anti-acetylcholine receptor monoclonal autoantibodies from the peripheral blood of a myasthenia gravis patient using combinatorial libraries. Rey E; Zeidel M; Rhine C; Tami J; Krolick K; Fischbach M; Sanz I Clin Immunol; 2000 Sep; 96(3):269-79. PubMed ID: 10964546 [TBL] [Abstract][Full Text] [Related]
2. Isolation and characterization of human anti-acetylcholine receptor monoclonal antibodies from transgenic mice expressing human immunoglobulin loci. Protopapadakis E; Kokla A; Tzartos SJ; Mamalaki A Eur J Immunol; 2005 Jun; 35(6):1960-8. PubMed ID: 15915538 [TBL] [Abstract][Full Text] [Related]
3. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera. Tzartos SJ; Sophianos D; Efthimiadis A J Immunol; 1985 Apr; 134(4):2343-9. PubMed ID: 3973387 [TBL] [Abstract][Full Text] [Related]
4. Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies. Graus YF; de Baets MH; Parren PW; Berrih-Aknin S; Wokke J; van Breda Vriesman PJ; Burton DR J Immunol; 1997 Feb; 158(4):1919-29. PubMed ID: 9029134 [TBL] [Abstract][Full Text] [Related]
5. Sequence analysis of anti-AChR antibodies in experimental autoimmune myasthenia gravis. Graus Y; Meng F; Vincent A; van Breda Vriesman P; de Baets M J Immunol; 1995 Jun; 154(12):6382-96. PubMed ID: 7539019 [TBL] [Abstract][Full Text] [Related]
6. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope. Atassi MZ; Oshima M; Deitiker P Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597 [TBL] [Abstract][Full Text] [Related]
7. Use of Torpedo-mouse hybrid acetylcholine receptors reveals immunodominance of the alpha subunit in myasthenia gravis antisera. Loutrari H; Tzartos SJ; Claudio T Eur J Immunol; 1992 Nov; 22(11):2949-56. PubMed ID: 1385157 [TBL] [Abstract][Full Text] [Related]
8. Structural characterization of the main immunogenic region of the Torpedo acetylcholine receptor. Morell SW; Trinh VB; Gudipati E; Friend A; Page NA; Agius MA; Richman DP; Fairclough RH Mol Immunol; 2014 Mar; 58(1):116-31. PubMed ID: 24333757 [TBL] [Abstract][Full Text] [Related]
9. Bacterial expression of a single-chain Fv fragment which efficiently protects the acetylcholine receptor against antigenic modulation caused by myasthenic antibodies. Mamalaki A; Trakas N; Tzartos SJ Eur J Immunol; 1993 Aug; 23(8):1839-45. PubMed ID: 8344344 [TBL] [Abstract][Full Text] [Related]
10. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors. Araga S; Galin FS; Kishimoto M; Adachi A; Blalock JB J Immunol; 1996 Jul; 157(1):386-92. PubMed ID: 8683141 [TBL] [Abstract][Full Text] [Related]
11. Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor. Barchan D; Asher O; Tzartos SJ; Fuchs S; Souroujon MC Eur J Immunol; 1998 Feb; 28(2):616-24. PubMed ID: 9521072 [TBL] [Abstract][Full Text] [Related]
12. Isolation and functional characterization of anti-acetylcholine receptor subunit-specific autoantibodies from myasthenic patients: receptor loss in cell culture. Sideris S; Lagoumintzis G; Kordas G; Kostelidou K; Sotiriadis A; Poulas K; Tzartos SJ J Neuroimmunol; 2007 Sep; 189(1-2):111-7. PubMed ID: 17617475 [TBL] [Abstract][Full Text] [Related]
13. [Antibodies in myasthenia gravis]. Eymard B Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288 [TBL] [Abstract][Full Text] [Related]
14. Evidence against acetylcholine receptor having a main immunogenic region as target for autoantibodies in myasthenia gravis. Lennon VA; Griesmann GE Neurology; 1989 Aug; 39(8):1069-76. PubMed ID: 2474772 [TBL] [Abstract][Full Text] [Related]
15. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. Loutrari H; Kokla A; Tzartos SJ Eur J Immunol; 1992 Sep; 22(9):2449-52. PubMed ID: 1516631 [TBL] [Abstract][Full Text] [Related]
16. Myasthenia gravis studied by monoclonal antibodies to the acetylcholine receptor. Tzartos SJ In Vivo; 1988; 2(1):105-10. PubMed ID: 2979808 [TBL] [Abstract][Full Text] [Related]
17. IgG from "seronegative" myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor. Blaes F; Beeson D; Plested P; Lang B; Vincent A Ann Neurol; 2000 Apr; 47(4):504-10. PubMed ID: 10762162 [TBL] [Abstract][Full Text] [Related]
18. Towards antigen-specific apheresis of pathogenic autoantibodies as a further step in the treatment of myasthenia gravis by plasmapheresis. Zisimopoulou P; Lagoumintzis G; Kostelidou K; Bitzopoulou K; Kordas G; Trakas N; Poulas K; Tzartos SJ J Neuroimmunol; 2008 Sep; 201-202():95-103. PubMed ID: 18667243 [TBL] [Abstract][Full Text] [Related]
19. Enzyme-linked immunosorbent assay for antibody against the nicotinic acetylcholine receptor in human myasthenia gravis. Kawanami S; Tsuji R; Oda K Ann Neurol; 1984 Feb; 15(2):195-200. PubMed ID: 6367620 [TBL] [Abstract][Full Text] [Related]